胰高血糖素样肽-1受体激动剂在肿瘤发生发展中的研究进展  

Progress of glucagon-like peptide-1 receptor agonists in development of tumors

作　　者：李玲玲 吕海宏[1,2] LI Ling-ling;LU Hai-hong(The First Clinical Medical College of Lanzhou University,Lanzhou GANSU 730000,China;Department of Endocrinology,the First Hospital of Lanzhou University,Lanzhou GANSU 730000,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院内分泌科,甘肃兰州730000

出　　处：《中国新药与临床杂志》2023年第7期417-422,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：甘肃省自然科学基金(21JR1RA080)。

摘　　要：胰高血糖素样肽-1受体激动剂(GLP-1RAs)是一种新型降糖药物,因降糖效果显著且低血糖发生风险小广泛用于2型糖尿病(T2DM)治疗。有研究报道GLP-1RAs会增加啮齿动物甲状腺髓样癌的发生风险,且胰高血糖素样肽-1受体存在于人体多种组织,因此GLP-1RAs与T2DM患者肿瘤发生、发展及预后的关系越来越受到人们关注。本文就GLP-1RAs与甲状腺髓样癌、胰腺癌、结直肠癌、前列腺癌、乳腺癌及部分生殖系统肿瘤的关系进行介绍。Glucagon-like peptide-1 receptor agonist(GLP-1RAs)is a new type of hypoglycemic drug,widely used in the treatment of type 2 diabetes mellitus(T2DM)due to its significant hypoglycemic effect and low risk of hypoglycemia.GLP-1RAs has been reported to increase the risk of medullary thyroid carcinoma in rodents,and the glucagon-like peptid-1 receptor is present in a variety of human tissues.Therefore,the relationship between GLP-1RAs and tumor occurrence,development and prognosis in T2DM patients has attracted increasing attention.The relationship between GLP-1RAs and medullary thyroid cancer,pancreatic cancer,colorectal cancer,prostate cancer,breast cancer and reproductive system tumors have been introduced in this article.

关 键 词：胰高血糖素样肽-1受体 降血糖药 糖尿病 2型 致癌作用 

分 类 号：R392.11[医药卫生—免疫学] R977.15[医药卫生—基础医学]